NCT03897881 — intismeran autogene (mRNA-4157) neoantigen vaccine trial
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)
Intismeran autogene (mRNA-4157 / V940), Moderna + Merck — KEYNOTE-942 randomized Phase 2b, adjuvant melanoma
Registry record
| Registry ID | NCT03897881 ↗ |
|---|---|
| Lead sponsor | ModernaTX, Inc. |
| Collaborators | Merck Sharp & Dohme LLC |
| Phase | Phase 2 |
| Status | Active Not Recruiting |
| Indication | Melanoma |
| Enrollment | 267 participants (target) |
| Start date | 2019-07-18 |
| Primary completion | 2032-11-30 (est.) |
| Last registry update | 3 Dec 2025 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT03897881), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
Daily coverage of the modality, tumor type and players this study touches:
Related trials
FAQ
What phase is NCT03897881?
NCT03897881 (An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)) is registered on ClinicalTrials.gov as Phase 2, sponsored by ModernaTX, Inc..
Is NCT03897881 recruiting?
As of the 2025-12-03 registry update, NCT03897881 is listed as "Active Not Recruiting". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT03897881?
The lead sponsor is ModernaTX, Inc.. Collaborators: Merck Sharp & Dohme LLC.
What condition does NCT03897881 study?
The registered condition is Melanoma. Primary completion is listed as 2032-11-30 (estimated).
Are results available for NCT03897881?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT03897881.
Back to the full neoantigen vaccine trial tracker — 107 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.